What’s up everyone, so in this video I’m going to be sharing with you updates on one
stock in a sector which is very close to my heart and about to change lives. And that’s
a biotech stock which is making big progress on radiotherapy for the treatment of cancer.
And before your brush this one off like any other biotech stock,
you need to give some attention to this stock and get it on your watchlist for a number of reasons
which include 2 major catalysts before the end of the year which the markets are raving about,
the investment bank Cantor has this as one of the top 3 biotech stocks to watch for Q4 given the
catalysts they hold, they are well funded through to 2025 and last but not the least they are green
on the year which shows you how much conviction the markets have in them. We are talking of a bear
market environment right now but the shareholders of this stock are sitting in the green and they
have more in the tank due imminently which could take them places before year end.
The global radiation therapy in oncology market size is expected to reach USD 8.86 Billion at a
revenue CAGR of 5.08% in 2030, according to latest analysis by Emergen Research. And radiotherapy is
one of the three most widely used cancer treatment modalities, along with surgery and chemotherapy.
Radiation methods of cancer therapy are non-invasive and can be used in combination with
other cancer therapies, with the most common type of radiation therapy being external beam radiation
therapy, which uses a machine outside the body to direct high-energy waves toward the tumor cells.
So the increasing prevalence of cancer across the globe is a key factor expected to drive
growth of the market over the forecast period. Rising government initiatives
for early detection and treatment of cancer is another key factor fueling growth of the market.
And our stock today is developing targeted radiotherapies that deliver cancer-killing
radiation with cellular-level precision Leukemia Cure...and
the Market Looks Lucrative. The leukemia therapeutics market could
reach $17.1 billion by 2024 from $12.3 billion in 2019, at a CAGR of 6.8%.
That said please drop a quick like on the video and hit the bell,
so we can get on with it with and talk about Actinium Pharmaceuticals Inc (NYSE:
ATNM) which is now sitting at over $7 per share with a market cap $179m. And on a ytd perspective
it is sitting up 11% which is a rare performance given the year we have faced so far and I believe
that if you were to do an assessment of the top 30 or 40 best performing stocks on this market,
I wouldn’t be surprised if Actinum makes the shortlist given the year they have had.
As with most biotech stocks, one would expect wild levels of volatility but what’s interesting
here is that the recent jumps with this play have mostly held up which tells of the level
of conviction the markets have in their drug pipeline and the strength of their R&D technology.
Triggers here would be their milestone updates and FDA announcements on the stock and the progress of
their developments which could see it go places as early as Q4. And as we always aim to buy low and
sell high you want to ensure you do your DD and get in only at a price which is right for you,
as patience is always required in this space. So here’s what’s new with Actinum.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company,
developing targeted radiotherapies to deliver cancer-killing radiation with cellular level
precision to treat patients with high unmet needs, not addressed by traditional cancer therapies.
Actinium's current clinical pipeline is led by ARCs or Antibody Radiation-Conjugates that are
being applied to targeted conditioning, which is intended to selectively deplete a patient's
disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant,
Gene Therapy or Adoptive Cell Therapy (ACT) such
as CAR-T to enable engraftment of these transplanted cells with minimal toxicities.
Actinium's targeted conditioning ARCs seek to improve patient outcomes and
access to these potentially curative treatments by eliminating or reducing
the non-targeted chemotherapy that is used for conditioning in standard practice currently.
Their lead product candidate, Iomab-B has been studied in several hundred
patients including in the recently completed, 150-patient, pivotal Phase 3 Study of Iomab-B
in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.
So some good progress there and building on this here’s what got the market cheering for Actinum
late in September, which you need to be aware and you may need to save some dates as well.
Actinium provided updates on their Iomab-B SIERRA Trial and Corporate
Updates Highlighting Key Upcoming Milestones. They said they were on
track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022.
The overall survival data from the Actimab-A CLAG-M combination trial is expected in Q4 2022.
Additional updates on collaborations and pipeline progress is demonstrating Actinium's leadership in
the development of Actinium--based radiotherapies expected by year-end. They had spproximately $116
million in cash at the end of Q2 2022 expected to fund key milestones development through mid-2025.
Sandesh Seth, their Chairman and CEO said Iomab-B represents a potential paradigm change in the
way difficult acute myeloid leukemia (AML) patients with active disease can be treated
with a potentially curative bone marrow transplant (BMT),". "Iomab-B enables elderly AML patients who
are relapsed or refractory to current therapies, access to a bone marrow transplant without being
in remission, whereas current conditioning regimens require patients to be in remission.
And if successful, the SIERRA trial results will demonstrate both improved access and outcomes,
in transplanted patients, who currently survive just a few months as they are not
treatable with currently available drugs and cannot be transplanted.
And over time, Iomab-B which has been tested in multiple, hard-to-treat blood cancers, has the
potential to become a universal conditioning regimen that can improve access and outcomes
compared to current non-targeted conditioning regimens for hematological malignancies."
What an opportunity and how game changing could that be.
"In addition to the impending pivotal trial results, they are looking forward
to presenting survival data from the Actimab-A CLAG-M combination trial in Q4 2022, which will
demonstrate the progress they are making with their research programs and collaborations.
Their strong balance sheet provides ample runway through mid-2025 which enables them
to deliver value creation driven by key clinical data, regulatory milestones and
R&D program advancement. These updates will enable Actinium to continue to demonstrate
its position as the leading, late-stage radiotherapeutics company developing highly
differentiated product candidates in diseases with high unmet or underserved medical needs.
Analysts at Seeking Alpha say that Actinium’s 2 Catalysts Before End Of 2022 Could Boost Value.
They say prior studies shows that 100% of patients who received Iomab-B were able to go on to receive
BMT and engraftment without any type of delay. The results from phase 1 study using Actimab-A in
combination with CLAG-M for the treatment of acute myeloid leukemia patients expected Q4 of 2022.
And the reason why Actimab-A might be an important program to move forward is because
it allows the treatment of AML patients to receive radiation at the cellular level,
which is not possible with traditional external beam radiation. So with a proof of concept
established with Iomab-B as a conditioning agent for AML, plus a few catalysts expected
before the end of 2022, they believe Actinium it is a great speculative biotech play to look
into as they provide investors with two potential opportunities to see a boost in shareholder value.
The IB Cantor listed three “high conviction” Phase 3 biotech readouts planned for Q4,22.
And On Actinium (ATNM), they cites topline data expected
for the company's lead asset Iomab-B from a pivotal Phase 3 trial involving those
aged 55 years and above with relapsed or refractory acute myeloid leukemia (AML).
They see no financial overhang on the company,
and they think positive Phase 3 results could lead to >100% upside to the share price..
They are also forecasting $360M peak net sales for Iomab-B, which I think is very bullish.
These aren't just the only two drugs in the company's pipeline either as they are applying its
radiotherapy technology towards other indications, including solid tumors. Plus, there is also the
possibility that its technology can be used as a preconditioning agent for other treatment options.
Biotech stocks are either hit or miss. But when they hit, the potential upside can be massive.
Actinium Pharmaceuticals (NYSE: ATNM) could be the latest and most significant
find in the biotech sector as It has a potentially revolutionary treatment
rapidly progressing and the possibility to change the treatment of cancer.
How very exciting?? So some very very interesting and mind blowing prospects ahead for this oncology
penny stock, but only consider getting in if the price is right for you and if you fully understand
the risks. This video is not financial advice, a buy or a sell recommendation, but is meant
to bring some new and exciting penny stocks to your attention for you to do your own research..
As always I would love to hear from you, so please let me know your thoughts on these top penny
stocks in the comments section below and what other penny stocks are catching your eyes lately.
And If you are new to my channel, please ensure to subscribe and hit the bell so you are notified
when I upload new videos. If you would like to see more videos like this, please check out this
video right here or this playlist right here to watch equally insightful content from the channel.
Thank you so much for being here and I look forward to have you in my next video. Thank you